Podcast

The 'Week in Review' - 27 January January 27, 2023

Another week of consternation about the health technology assessment review and some questions from the audience, including one that challenges the exclusion of people from the consultation process but another that doubts there was any alternative.

Forget about experts and terms of reference until we get a transparent process January 27, 2023

The HTA review reference committee will meet today with a published but vaguely worded agenda that should include a discussion on creating a transparent process with the release of all relevant documents.

Australia Day recognition for senior officials and pharmacy leaders January 27, 2023

Recognition for a former health department leader, other officials and pharmacists in this year's Australia Day Honours List.

Is this a change of heart from the former health department secretary? January 27, 2023

Former health department secretary Glenys Beauchamp AO PSM says the government should speak directly to the public about policy ahead of peak bodies and be more open and transparent in its decision-making.

New chair for Australian genomics industry organisation January 26, 2023

Australian genomics industry organisation InGeNA has appointed leading digital health executive Kathy Campbell as its chair for 2023-24.

MEDLAB receives Import Certificate from UK Home Office for NanaBis January 26, 2023

Medlab Clinical (ASX:MDC) has announced that its NanaBis has been issued import certification by the UK Home Office.

Alterity Therapeutics launches ATH434 Phase 2 clinical trial in Italy January 26, 2023

Alterity Therapeutics (ASX:ATH) has announced that its Phase 2 trial of ATH434 for treating patients with Multiple System Atrophy is now open for enrollment in Italy.

EMVision says clinical trial progressing and ASA milestone achieved January 26, 2023

EMVision Medical Devices (ASX:EMV) has provided an update on its clinical trial and achieved a technical development milestone.

Immuron and partners respond to FDA clinical hold January 26, 2023

Australian biopharmaceutical company Immuron (ASX:IMC) has submitted a response letter to the US FDA in response to its clinical hold on trials of the new oral therapeutic targeting campylobacter.

FDA approves IND for Prader-Willi syndrome study of Neuren's NNZ-2591 January 26, 2023

Neuren Pharmaceuticals (ASX:NEU) has announced that the US FDA has reviewed Neuren’s Investigational New Drug application for NNZ-2591 in Prader-Willi syndrome.

PharmAust progresses to elevated doses of MPL in Motor Neurone Disease January 26, 2023

PharmAust (ASX:PAA) has announced that the Trial Safety Committee has approved an escalation of the Monepantel dose in a trial in patients with Motor Neurone Disease.

Chimeric Therapeutics updates on CLTX CAR T clinical trial January 26, 2023

Clinical-stage cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that all patients dosed in the third cohort of a clinical trial have advanced beyond the 28-day follow-up period without experiencing dose-limiting toxicities.

Latest Video

Most Read

Australia Day recognition for senior officials and pharmacy leaders

The event will focus on reviews, reform processes and now tenders

Forget about experts and terms of reference until we get a transparent process

Is this a change of heart from the former health department secretary?

The 'Week in Review' - 27 January

New Stories

The 'Week in Review' - 27 January

Forget about experts and terms of reference until we get a transparent process

Australia Day recognition for senior officials and pharmacy leaders

Is this a change of heart from the former health department secretary?

New chair for Australian genomics industry organisation

MEDLAB receives Import Certificate from UK Home Office for NanaBis

Alterity Therapeutics launches ATH434 Phase 2 clinical trial in Italy

Sign In

Latest Video

Most Read

Australia Day recognition for senior officials and pharmacy leaders

The event will focus on reviews, reform processes and now tenders

Forget about experts and terms of reference until we get a transparent process

Is this a change of heart from the former health department secretary?

The 'Week in Review' - 27 January

Follow Us

New Stories

The 'Week in Review' - 27 January

Forget about experts and terms of reference until we get a transparent process

Australia Day recognition for senior officials and pharmacy leaders

Is this a change of heart from the former health department secretary?

New chair for Australian genomics industry organisation

MEDLAB receives Import Certificate from UK Home Office for NanaBis

Alterity Therapeutics launches ATH434 Phase 2 clinical trial in Italy